Assessment of Patient Experiences with Respimat® in Everyday Clinical Practice

Christian Taube, Valentina Bayer, Christoph Michael Zehendner, Arschang Valipour, Christian Taube, Valentina Bayer, Christoph Michael Zehendner, Arschang Valipour

Abstract

Introduction: Chronic obstructive pulmonary disease (COPD) is a progressive disease requiring maintenance therapy. According to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) strategy report, bronchodilation with long-acting muscarinic antagonists (LAMAs) and long-acting β2-agonists (LABAs), administered via inhalers, is currently the mainstay of COPD treatment. Combined LAMA/LABA therapies have been shown to improve patient health status, lung function and breathlessness. Here, we wanted to report patient satisfaction with the Respimat® Soft Mist™ inhaler (SMI).

Methods: This was a pooled analysis of SPIRIT® (NCT02675517) and OTIVACTO® (NCT02719639), two open-label, single-arm, non-interventional studies of physical function in patients with COPD. Patients were treated with tiotropium/olodaterol 5/5 μg for approximately 6 weeks via the SMI. SPIRIT was conducted in Germany; OTIVACTO was conducted in nine European countries. The primary endpoints have been reported previously. Here, we assess patient satisfaction with inhalation and handling, and patient adherence to treatment with the tiotropium/olodaterol SMI in patients with COPD. These were assessed through self-reported questionnaires and physician general assessments.

Results: Baseline data were collected from 9180 patients from the SPIRIT and OTIVACTO studies. The majority of patients were GOLD group A (25.59%) or B (46.12%). After 6 weeks of treatment with tiotropium/olodaterol, 85.78% of patients were 'satisfied' or 'very satisfied' with inhaling from the device, and 84.33% of patients were 'satisfied' or 'very satisfied' with the handling of the inhaler. Treating physicians reported patient adherence as 'high' during the study, with 98.57% of patients regularly using the tiotropium/olodaterol SMI. Furthermore, 95.45% of patients expressed a willingness to continue using the tiotropium/olodaterol SMI at the end of the observation period.

Conclusion: In this study, over 9000 patients reported satisfaction with respect to inhalation and handling of the Respimat SMI, and patient adherence was high.

Trial registration: ClinicalTrials.gov: NCT02675517 (SPIRIT) and NCT02719639 (OTIVACTO).

Keywords: Bronchodilator; COPD; Inhaler; Non-interventional studies; OTIVACTO; Observational patient satisfaction; SPIRIT; Soft Mist.

Figures

Fig. 1
Fig. 1
a Patient overall satisfaction with inhalation from the Respimat device after week 6. b Patient overall satisfaction with handling of the Respimat device after week 6. ‘Not applicable’ applies to a small percentage of the total population (n = 4 [0.04%]) who did not complete the questionnaire. GOLD, Global Initiative for Chronic Obstructive Lung Disease
Fig. 2
Fig. 2
a Regular use of Respimat during treatment. b Patients reporting continued use of Respimat after end of observation. GOLD, Global Initiative for Chronic Obstructive Lung Disease

References

    1. Lopez-Campos JL, Calero C, Quintana-Gallego E. Symptom variability in COPD: a narrative review. Int J Chronic Obstruct Pulmon Dis. 2013;8:231–238. doi: 10.2147/COPD.S42866.
    1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2020 report). 2019. . Cited 15 June 2020.
    1. Lavorini F, Janson C, Braido F, Stratelis G, Løkke A. What to consider before prescribing inhaled medications: a pragmatic approach for evaluating the current inhaler landscape. Ther Adv Respir Dis. 2019;13:1753466619884532. doi: 10.1177/1753466619884532.
    1. Miravitlles M, Soler-Cataluña JJ, Alcázar B, Viejo JL, García-Río F. Factors affecting the selection of an inhaler device for COPD and the ideal device for different patient profiles. Results of EPOCA Delphi consensus. Pulmon Pharmacol Ther. 2018;48:97–103. doi: 10.1016/j.pupt.2017.10.006.
    1. van der Palen J, Ginko T, Kroker A, et al. Preference, satisfaction and errors with two dry powder inhalers in patients with COPD. Expert Opin Drug Deliv. 2013;10(8):1023–1031. doi: 10.1517/17425247.2013.808186.
    1. Usmani OS, Lavorini F, Marshall J, et al. Critical inhaler errors in asthma and COPD: a systematic review of impact on health outcomes. Respir Res. 2018;19(1):10. doi: 10.1186/s12931-017-0710-y.
    1. Duarte-de-Araujo A, Teixeira P, Hespanhol V, Correia-de-Sousa J. COPD: analysing factors associated with a successful treatment. Pulmonology. 2020;26(2):66–72. doi: 10.1016/j.pulmoe.2019.05.012.
    1. Sanduzzi A, Balbo P, Candoli P, et al. COPD: adherence to therapy. Multidiscip Respir Med. 2014;9(1):60. doi: 10.1186/2049-6958-9-60.
    1. Ghosh S, Pleasants RA, Ohar JA, Donohue JF, Drummond MB. Prevalence and factors associated with suboptimal peak inspiratory flow rates in COPD. Int J Chronic Obstruct Pulmon Dis. 2019;14:585–595. doi: 10.2147/COPD.S195438.
    1. Anderson P. Use of Respimat Soft Mist inhaler in COPD patients. Int J Chronic Obstruct Pulmon Dis. 2006;1(3):251–259.
    1. Dhand R, Eicher J, Hansel M, Jost I, Meisenheimer M, Wachtel H. Improving usability and maintaining performance: human-factor and aerosol-performance studies evaluating the new reusable Respimat inhaler. Int J Chronic Obstruct Pulmon Dis. 2019;14:509–523. doi: 10.2147/COPD.S190639.
    1. Dalby RN, Eicher J, Zierenberg B. Development of Respimat® Soft Mist Inhaler and its clinical utility in respiratory disorders. Med Devices (Auckl, NZ) 2011;4:145–155.
    1. Sorino C, Negri S, Spanevello A, Visca D, Scichilone N. Inhalation therapy devices for the treatment of obstructive lung diseases: the history of inhalers towards the ideal inhaler. Eur J Intern Med. 2020;75:15–18. doi: 10.1016/j.ejim.2020.02.023.
    1. Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J. 2002;19(2):217–224. doi: 10.1183/09031936.02.00269802.
    1. O'Donnell DE, Fluge T, Gerken F, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J. 2004;23(6):832–840. doi: 10.1183/09031936.04.00116004.
    1. Buhl R, Maltais F, Abrahams R, et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4) Eur Respir J. 2015;45(4):969–979. doi: 10.1183/09031936.00136014.
    1. Ferguson GT, Karpel J, Bennett N, et al. Effect of tiotropium and olodaterol on symptoms and patient-reported outcomes in patients with COPD: results from four randomised, double-blind studies. NPJ Prim Care Respir Med. 2017;27(1):7. doi: 10.1038/s41533-016-0002-x.
    1. Nici L, Mammen MJ, Charbek E, et al. Pharmacologic management of COPD: an official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med. 2020;201(9):e56–e69. doi: 10.1164/rccm.202003-0625ST.
    1. National Institute for Health and Care Excellence. Chronic obstructive pulmonary disease in over 16s: diagnosis and management. 2019. . Cited 15 June 2020.
    1. Valipour A, Tamm M, Kociánová J, et al. Improvement of self-reported physical functioning with tiotropium/olodaterol in Central and Eastern European COPD patients. Int J Chronic Obstruct Pulmon Dis. 2019;14:2343–2354. doi: 10.2147/COPD.S204388.
    1. Steinmetz KO, Abenhardt B, Pabst S, et al. Assessment of physical functioning and handling of tiotropium/olodaterol Respimat® in patients with COPD in a real-world clinical setting. Int J Chronic Obstruct Pulmon Dis. 2019;14:1441–1453. doi: 10.2147/COPD.S195852.
    1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of COPD. 2017. . Cited 15 June 2020.
    1. López-Campos JL, Quintana Gallego E, Carrasco HL. Status of and strategies for improving adherence to COPD treatment. Int J Chronic Obstruct Pulmon Dis. 2019;14:1503–1515. doi: 10.2147/COPD.S170848.
    1. Khurana AK, Dubey K, Goyal A, Pawar KS, Phulwaria C, Pakhare A. Correcting inhaler technique decreases severity of obstruction and improves quality of life among patients with obstructive airway disease. J Fam Med Prim Care. 2019;8(1):246–250. doi: 10.4103/jfmpc.jfmpc_259_18.
    1. Pothirat C, Chaiwong W, Phetsuk N, Pisalthanapuna S, Chetsadaphan N, Choomuang W. Evaluating inhaler use technique in COPD patients. Int J Chronic Obstruct Pulmon Dis. 2015;10:1291–1298. doi: 10.2147/COPD.S85681.
    1. Duarte-de-Araujo A, Teixeira P, Hespanhol V, Correia-de-Sousa J. COPD: misuse of inhaler devices in clinical practice. Int J Chronic Obstruct Pulmon Dis. 2019;14:1209–1217. doi: 10.2147/COPD.S178040.
    1. Miravitlles M, Montero-Caballero J, Richard F, et al. A cross-sectional study to assess inhalation device handling and patient satisfaction in COPD. Int J Chronic Obstruct Pulmon Dis. 2016;11:407–415. doi: 10.2147/COPD.S91118.
    1. Chrystyn H, Small M, Milligan G, Higgins V, Gil EG, Estruch J. Impact of patients' satisfaction with their inhalers on treatment compliance and health status in COPD. Respir Med. 2014;108(2):358–365. doi: 10.1016/j.rmed.2013.09.021.
    1. Navaie M, Dembek C, Cho-Reyes S, Yeh K, Celli BR. Device use errors with soft mist inhalers: a global systematic literature review and meta-analysis. Chronic Respir Dis. 2020;17:1479973119901234. doi: 10.1177/1479973119901234.
    1. Wachtel H, Kattenbeck S, Dunne S, Disse B. The Respimat® development story: patient-centered innovation. Pulmon Ther. 2017;3:19–30. doi: 10.1007/s41030-017-0040-8.
    1. Hänsel M, Bambach T, Wachtel H. Reduced environmental impact of the reusable Respimat® Soft Mist™ inhaler compared with pressurised metered-dose inhalers. Adv Ther. 2019;36(9):2487–2492. doi: 10.1007/s12325-019-01028-y.
    1. Forster A, Sauer R, Mattiucci-Gühlke M, Berneburg J. Assessment of patient satisfaction and preference with the Respimat®. Pneumologie. 2020;74(S 01):P537.
    1. Schurmann W, Schmidtmann S, Moroni P, Massey D, Qidan M. Respimat Soft Mist inhaler versus hydrofluoroalkane metered dose inhaler: patient preference and satisfaction. Treat Respir Med. 2005;4(1):53–61. doi: 10.2165/00151829-200504010-00006.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera